Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trametinib effect on oral contraceptive pharmacokinetics in women with solid tumors
NL-OMON47513Phase 1Active, not recruiting
- Sponsor
- Novartis
- Start
- Oct 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of trametinib, norethindrone and ethinyl estradiol in Nonhematologic neoplasms, sponsored by Novartis. Primary endpoint: Effect of multiple daily doses of trametinib on steady-state pharmacokinetics of norethindrone and ethinyl estradiol. Started Oct 2016; status: active, not recruiting.
02
Drugs
trametinibnorethindroneethinyl estradiol
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on NL-OMON47513.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47513.